Corey J Langer1, Mary W Redman2, James L Wade3, Charu Aggarwal4, Jeffrey D Bradley5, Jeffrey Crawford6, Philip J Stella7, Mark H Knapp8, Jieling Miao2, Katherine Minichiello2, Roy S Herbst9, Karen Kelly10, David R Gandara10, Vassiliki A Papadimitrakopoulou11. 1. University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: Corey.Langer@uphs.upenn.edu. 2. SWOG Statistics and Data Management Center at Fred Hutchinson Cancer Research Center, Seattle, Washington. 3. Heartland NCORP, Decatur, Illinois. 4. University of Pennsylvania, Philadelphia, Pennsylvania. 5. Washington University School of Medicine, St. Louis, Missouri. 6. Duke University Medical Center, Durham, North Carolina. 7. Michigan CRC NCORP/IHA Hematology Oncology Consultants, Ypsilanti, Michigan. 8. Columbus NCORP/The Mark H. Zangmeister Center, Westerville, Ohio. 9. Medical Oncology, Yale Cancer Center, New Haven, Connecticut. 10. University of California Davis Cancer Center, Sacramento, California. 11. Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Abstract
BACKGROUND: S1400B is a biomarker-driven Lung-MAP substudy evaluating the phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (GDC-0032) in patients with PI3K pathway-activated squamous NSCLC (sqNSCLC). METHODS: Eligible patients had tumoral phosphatidylinositol-4,5-biphosphate 3 kinase catalytic subunit alpha (PIK3CA) alterations by next-generation sequencing and disease progression after at least one line of platinum-based therapy. Patients received 4-mg taselisib orally daily. The primary analysis population (PAP) was a subset of patients having substitution mutations believed to be associated with clinical benefit of PI3K inhibitors. Primary endpoint was response by Response Evaluation Criteria in Solid Tumors version 1.1; secondary endpoints included progression-free survival, overall survival and duration of response. RESULTS: Twenty-six patients treated with taselisib comprised the full evaluable population (FEP); 21 patients comprised the PAP. Median age for patients in the FEP was 68 years (range: 53-83 years), 19 were male (73%). The study was closed for futility at interim analysis with one responder in the PAP (5% response rate, 95% confidence interval [CI]: 0%-24%). Two possibly treatment-related deaths (one respiratory failure, one cardiac arrest) were observed; one patient had grades 4 and 11 had grade 3 adverse events. Median progression-free survival and overall survival in the PAP group were 2.9 months (95% CI: 1.8-4.0 mo) and 5.9 months (95% CI: 4.2-7.8 mo), respectively. These numbers were nearly the same in the FEP. CONCLUSIONS: Study S1400B evaluating taselisib in PIK3CA-altered sqNSCLC failed to meet its primary endpoint and was closed after an interim futility analysis. The trial is unique in cataloguing the diversity of PIK3CA mutations in sqNSCLC.
BACKGROUND: S1400B is a biomarker-driven Lung-MAP substudy evaluating the phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (GDC-0032) in patients with PI3K pathway-activated squamous NSCLC (sqNSCLC). METHODS: Eligible patients had tumoralphosphatidylinositol-4,5-biphosphate 3 kinase catalytic subunit alpha (PIK3CA) alterations by next-generation sequencing and disease progression after at least one line of platinum-based therapy. Patients received 4-mg taselisib orally daily. The primary analysis population (PAP) was a subset of patients having substitution mutations believed to be associated with clinical benefit of PI3K inhibitors. Primary endpoint was response by Response Evaluation Criteria in Solid Tumors version 1.1; secondary endpoints included progression-free survival, overall survival and duration of response. RESULTS: Twenty-six patients treated with taselisib comprised the full evaluable population (FEP); 21 patients comprised the PAP. Median age for patients in the FEP was 68 years (range: 53-83 years), 19 were male (73%). The study was closed for futility at interim analysis with one responder in the PAP (5% response rate, 95% confidence interval [CI]: 0%-24%). Two possibly treatment-related deaths (one respiratory failure, one cardiac arrest) were observed; one patient had grades 4 and 11 had grade 3 adverse events. Median progression-free survival and overall survival in the PAP group were 2.9 months (95% CI: 1.8-4.0 mo) and 5.9 months (95% CI: 4.2-7.8 mo), respectively. These numbers were nearly the same in the FEP. CONCLUSIONS: Study S1400B evaluating taselisib in PIK3CA-altered sqNSCLC failed to meet its primary endpoint and was closed after an interim futility analysis. The trial is unique in cataloguing the diversity of PIK3CA mutations in sqNSCLC.
Authors: Achim Rittmeyer; Fabrice Barlesi; Daniel Waterkamp; Keunchil Park; Fortunato Ciardiello; Joachim von Pawel; Shirish M Gadgeel; Toyoaki Hida; Dariusz M Kowalski; Manuel Cobo Dols; Diego L Cortinovis; Joseph Leach; Jonathan Polikoff; Carlos Barrios; Fairooz Kabbinavar; Osvaldo Arén Frontera; Filippo De Marinis; Hande Turna; Jong-Seok Lee; Marcus Ballinger; Marcin Kowanetz; Pei He; Daniel S Chen; Alan Sandler; David R Gandara Journal: Lancet Date: 2016-12-13 Impact factor: 79.321
Authors: Julie Brahmer; Karen L Reckamp; Paul Baas; Lucio Crinò; Wilfried E E Eberhardt; Elena Poddubskaya; Scott Antonia; Adam Pluzanski; Everett E Vokes; Esther Holgado; David Waterhouse; Neal Ready; Justin Gainor; Osvaldo Arén Frontera; Libor Havel; Martin Steins; Marina C Garassino; Joachim G Aerts; Manuel Domine; Luis Paz-Ares; Martin Reck; Christine Baudelet; Christopher T Harbison; Brian Lestini; David R Spigel Journal: N Engl J Med Date: 2015-05-31 Impact factor: 91.245
Authors: Pierre P Massion; Peter M Taflan; Yu Shyr; S M Jamshedur Rahman; Pinar Yildiz; Bashar Shakthour; Mary E Edgerton; Matthew Ninan; Jeremiah J Andersen; Adriana L Gonzalez Journal: Am J Respir Crit Care Med Date: 2004-08-18 Impact factor: 21.405
Authors: Jill M Spoerke; Carol O'Brien; Ling Huw; Hartmut Koeppen; Jane Fridlyand; Rainer K Brachmann; Peter M Haverty; Ajay Pandita; Sankar Mohan; Deepak Sampath; Lori S Friedman; Leanne Ross; Garret M Hampton; Lukas C Amler; David S Shames; Mark R Lackner Journal: Clin Cancer Res Date: 2012-11-07 Impact factor: 12.531
Authors: Jeffrey A Engelman; Liang Chen; Xiaohong Tan; Katherine Crosby; Alexander R Guimaraes; Rabi Upadhyay; Michel Maira; Kate McNamara; Samanthi A Perera; Youngchul Song; Lucian R Chirieac; Ramneet Kaur; Angela Lightbown; Jessica Simendinger; Timothy Li; Robert F Padera; Carlos García-Echeverría; Ralph Weissleder; Umar Mahmood; Lewis C Cantley; Kwok-Kin Wong Journal: Nat Med Date: 2008-11-30 Impact factor: 53.440
Authors: Flávia Melo Cunha de Pinho Pessoa; Caio Bezerra Machado; Emerson Lucena da Silva; Laudreísa da Costa Pantoja; Rodrigo Monteiro Ribeiro; Maria Elisabete Amaral de Moraes; Manoel Odorico de Moraes Filho; Raquel Carvalho Montenegro; André Salim Khayat; Caroline Aquino Moreira-Nunes Journal: Int J Mol Sci Date: 2022-03-30 Impact factor: 5.923
Authors: Mary W Redman; Vassiliki A Papadimitrakopoulou; Katherine Minichiello; Fred R Hirsch; Philip C Mack; Lawrence H Schwartz; Everett Vokes; Suresh Ramalingam; Natasha Leighl; Jeff Bradley; Jieling Miao; James Moon; Louise Highleyman; Crystal Miwa; Michael L LeBlanc; Shakun Malik; Vincent A Miller; Ellen V Sigal; Stacey Adam; David Wholley; Caroline Sigman; Beverly Smolich; Charles D Blanke; Karen Kelly; David R Gandara; Roy S Herbst Journal: Lancet Oncol Date: 2020-10-27 Impact factor: 41.316